Nurix Therapeutics (NRIX) Competitors $22.92 -3.94 (-14.67%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends NRIX vs. ARVN, LGND, PRAX, CMPS, LEGN, ELAN, VKTX, CYTK, BPMC, and LNTHShould you be buying Nurix Therapeutics stock or one of its competitors? The main competitors of Nurix Therapeutics include Arvinas (ARVN), Ligand Pharmaceuticals (LGND), Praxis Precision Medicines (PRAX), COMPASS Pathways (CMPS), Legend Biotech (LEGN), Elanco Animal Health (ELAN), Viking Therapeutics (VKTX), Cytokinetics (CYTK), Blueprint Medicines (BPMC), and Lantheus (LNTH). These companies are all part of the "medical" sector. Nurix Therapeutics vs. Arvinas Ligand Pharmaceuticals Praxis Precision Medicines COMPASS Pathways Legend Biotech Elanco Animal Health Viking Therapeutics Cytokinetics Blueprint Medicines Lantheus Arvinas (NASDAQ:ARVN) and Nurix Therapeutics (NASDAQ:NRIX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, community ranking, risk, valuation, earnings and dividends. Does the MarketBeat Community believe in ARVN or NRIX? Arvinas received 109 more outperform votes than Nurix Therapeutics when rated by MarketBeat users. However, 78.02% of users gave Nurix Therapeutics an outperform vote while only 66.42% of users gave Arvinas an outperform vote. CompanyUnderperformOutperformArvinasOutperform Votes18066.42% Underperform Votes9133.58% Nurix TherapeuticsOutperform Votes7178.02% Underperform Votes2021.98% Do analysts prefer ARVN or NRIX? Arvinas presently has a consensus target price of $60.00, suggesting a potential upside of 166.90%. Nurix Therapeutics has a consensus target price of $29.40, suggesting a potential upside of 28.27%. Given Arvinas' higher possible upside, analysts plainly believe Arvinas is more favorable than Nurix Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arvinas 0 Sell rating(s) 1 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.93Nurix Therapeutics 0 Sell rating(s) 1 Hold rating(s) 14 Buy rating(s) 0 Strong Buy rating(s) 2.93 Is ARVN or NRIX more profitable? Arvinas has a net margin of 0.00% compared to Nurix Therapeutics' net margin of -313.65%. Arvinas' return on equity of -50.26% beat Nurix Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets ArvinasN/A -50.26% -24.87% Nurix Therapeutics -313.65%-63.39%-41.82% Does the media refer more to ARVN or NRIX? In the previous week, Arvinas had 1 more articles in the media than Nurix Therapeutics. MarketBeat recorded 3 mentions for Arvinas and 2 mentions for Nurix Therapeutics. Nurix Therapeutics' average media sentiment score of 1.27 beat Arvinas' score of 0.96 indicating that Nurix Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arvinas 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nurix Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher earnings and valuation, ARVN or NRIX? Nurix Therapeutics has lower revenue, but higher earnings than Arvinas. Nurix Therapeutics is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArvinas$78.50M19.68-$367.30M-$4.67-4.81Nurix Therapeutics$76.99M21.09-$143.95M-$2.91-7.88 Which has more volatility and risk, ARVN or NRIX? Arvinas has a beta of 1.96, indicating that its share price is 96% more volatile than the S&P 500. Comparatively, Nurix Therapeutics has a beta of 2.2, indicating that its share price is 120% more volatile than the S&P 500. Do institutionals and insiders believe in ARVN or NRIX? 95.2% of Arvinas shares are owned by institutional investors. 5.2% of Arvinas shares are owned by insiders. Comparatively, 7.2% of Nurix Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. SummaryArvinas and Nurix Therapeutics tied by winning 9 of the 18 factors compared between the two stocks. Ad Weiss RatingsThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin conference in Nashville … Where he told an adoring crowd that the U.S. would become … “The crypto capital of the planet and the Bitcoin superpower of the world.”Click here to find out more about what could be Trump and JD Vance’s favorite coin. Get Nurix Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NRIX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NRIX vs. The Competition Export to ExcelMetricNurix TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.62B$6.39B$5.06B$8.67BDividend YieldN/A8.04%5.06%4.06%P/E Ratio-7.8810.0598.5017.07Price / Sales21.09266.571,206.2371.30Price / CashN/A53.4940.6936.36Price / Book5.559.306.325.87Net Income-$143.95M$154.14M$119.47M$225.66M7 Day Performance-16.17%-9.49%-5.11%-1.34%1 Month Performance-11.20%-7.23%-3.21%1.00%1 Year Performance277.59%30.70%32.41%25.27% Nurix Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NRIXNurix Therapeutics2.6697 of 5 stars$22.92-14.7%$29.40+28.3%+277.6%$1.62B$76.99M-7.88300Positive NewsARVNArvinas2.3286 of 5 stars$26.17-6.7%N/A+8.1%$1.80B$78.50M-5.60445Short Interest ↓LGNDLigand Pharmaceuticals4.9911 of 5 stars$121.03-2.0%N/A+95.5%$2.21B$152.42M48.2280Analyst ForecastPRAXPraxis Precision Medicines1.7898 of 5 stars$83.14-2.0%N/A+398.0%$1.55B$1.61M-8.07110Insider SellingNews CoverageCMPSCOMPASS Pathways3.0373 of 5 stars$5.02-5.5%N/A-11.0%$343.47MN/A-2.28120Short Interest ↓Gap UpLEGNLegend Biotech1.8575 of 5 stars$40.30+0.6%N/A-39.9%$7.35B$455.99M-51.671,800Earnings ReportAnalyst ForecastShort Interest ↑Analyst RevisionNews CoverageELANElanco Animal Health3.5205 of 5 stars$14.19-0.6%N/A+21.5%$7.01B$4.42B35.489,300Short Interest ↑VKTXViking Therapeutics4.5045 of 5 stars$60.88-3.3%N/A+370.8%$6.78BN/A-65.4620CYTKCytokinetics4.0709 of 5 stars$56.30-4.0%N/A+58.5%$6.62B$7.53M-10.46250Insider SellingBPMCBlueprint Medicines3.0804 of 5 stars$97.19-2.7%N/A+41.6%$6.17B$249.38M-46.06640Analyst ForecastShort Interest ↑News CoverageLNTHLantheus4.6074 of 5 stars$84.95+1.0%N/A+12.7%$5.91B$1.30B14.13834 Related Companies and Tools Related Companies ARVN Alternatives LGND Alternatives PRAX Alternatives CMPS Alternatives LEGN Alternatives ELAN Alternatives VKTX Alternatives CYTK Alternatives BPMC Alternatives LNTH Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NRIX) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nurix Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nurix Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
